Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.